공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

암성 통증 : 파이프라인 리뷰

Cancer Pain (Central Nervous System) - Drugs in Development, 2021

리서치사 Global Markets Direct
발행일 2021년 09월 상품 코드 192514
페이지 정보 영문 169 Pages
가격
US $ 2,000 ₩ 2,395,000 PDF (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,790,000 PDF (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 7,185,000 PDF (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


암성 통증 : 파이프라인 리뷰 Cancer Pain (Central Nervous System) - Drugs in Development, 2021
발행일 : 2021년 09월 페이지 정보 : 영문 169 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

암성 통증이란 암에 의한 인체의 손상과 그 손상에 대한 인체 반응이 복잡하게 혼합된 감각으로 정의할 수 있습니다. 통증은 종양에 의한 인체 조직의 압박 및 침윤, 치료·진단을 위한 시술, 면역반응 및 호르몬 방출에 의한 피부·신경 등의 변형 등에 의해 발생합니다. 진통제 요법 및 오피오이드 진통제, 항원보강제(좌약), 심리요법, 마취학적·신경외과학적 통증 관리 방법 등에 의해 암성 통증을 치료할 수 있습니다.

세계 각국에서의 암성 통증(Cancer Pain) 치료용 파이프라인 제품 개발 상황에 대해 분석했으며, 제품 개발·출시의 최신 동향, 임상시험 각 단계별 제품 리스트, 주요 기업 개요, 주요 약제 개요, 최신 업계 동향 등의 정보를 정리하여 전해드립니다.

서론

암성 통증 : 개요

치료제 개발

치료제 평가

치료제 개발 참여 기업

약제 개요

휴지 상태인 프로젝트

개발이 중지된 제품

제품 개발 마일스톤

부록

도표

LSH 17.05.30

List of Tables

List of Tables

  • Number of Products under Development for Cancer Pain, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Companies, 2021 (Contd..1)
  • Number of Products under Development by Companies, 2021 (Contd..2)
  • Number of Products under Development by Universities/Institutes, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Companies, 2021 (Contd..1)
  • Products under Development by Companies, 2021 (Contd..2)
  • Products under Development by Universities/Institutes, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Target, 2021 (Contd..1)
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Mechanism of Action, 2021 (Contd..1)
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Cancer Pain - Pipeline by AfaSci Inc, 2021
  • Cancer Pain - Pipeline by Alexza Pharmaceuticals Inc, 2021
  • Cancer Pain - Pipeline by AngioChem Inc, 2021
  • Cancer Pain - Pipeline by Aphios Corp, 2021
  • Cancer Pain - Pipeline by Aquilus Pharmaceuticals Inc, 2021
  • Cancer Pain - Pipeline by AstraZeneca Plc, 2021
  • Cancer Pain - Pipeline by Beckley Canopy Therapeutics Ltd, 2021
  • Cancer Pain - Pipeline by Bisichem Co Ltd, 2021
  • Cancer Pain - Pipeline by Cassava Sciences Inc, 2021
  • Cancer Pain - Pipeline by Chengdu Easton Biopharmaceuticals Co Ltd, 2021
  • Cancer Pain - Pipeline by Concentric Analgesics Inc, 2021
  • Cancer Pain - Pipeline by Fujimoto Pharmaceutical Corp, 2021
  • Cancer Pain - Pipeline by IACTA Pharmaceuticals Inc, 2021
  • Cancer Pain - Pipeline by Indaptus Therapeutics Inc, 2021
  • Cancer Pain - Pipeline by IntelGenx Corp, 2021
  • Cancer Pain - Pipeline by iX Biopharma Ltd, 2021
  • Cancer Pain - Pipeline by Jiangsu Huatai Chenguang Pharmaceutical Co Ltd, 2021
  • Cancer Pain - Pipeline by Klaria Pharma Holding AB, 2021
  • Cancer Pain - Pipeline by Komipharm International Co Ltd, 2021
  • Cancer Pain - Pipeline by Luye Pharma Group Ltd, 2021
  • Cancer Pain - Pipeline by Medlab Clinical Ltd, 2021
  • Cancer Pain - Pipeline by Mundipharma International Ltd, 2021
  • Cancer Pain - Pipeline by Nanomerics Ltd, 2021
  • Cancer Pain - Pipeline by Neurocentrx Pharma Ltd, 2021
  • Cancer Pain - Pipeline by Nippon Zoki Pharmaceutical Co Ltd, 2021
  • Cancer Pain - Pipeline by Orion Corp, 2021
  • Cancer Pain - Pipeline by Pfizer Inc, 2021
  • Cancer Pain - Pipeline by ProNeurogen Inc, 2021
  • Cancer Pain - Pipeline by Quell Therapeutics Ltd, 2021
  • Cancer Pain - Pipeline by Ribomic Inc, 2021
  • Cancer Pain - Pipeline by Sedor Pharmaceuticals LLC, 2021
  • Cancer Pain - Pipeline by Shandong Boan Biotechnology Co Ltd, 2021
  • Cancer Pain - Pipeline by Sorrento Therapeutics Inc, 2021
  • Cancer Pain - Pipeline by Tetra Bio-Pharma Inc, 2021
  • Cancer Pain - Pipeline by Tris Pharma Inc, 2021
  • Cancer Pain - Pipeline by Virpax Pharmaceuticals Inc, 2021
  • Cancer Pain - Pipeline by WEX Pharmaceuticals Inc, 2021
  • Cancer Pain - Pipeline by Winston Pharmaceuticals Inc, 2021
  • Cancer Pain - Pipeline by Yichang Renfu Pharmaceutical Co Ltd, 2021
  • Cancer Pain - Pipeline by Yongzhan International Pharmaceutical Co Ltd, 2021
  • Cancer Pain - Dormant Projects, 2021
  • Cancer Pain - Dormant Projects, 2021 (Contd..1)
  • Cancer Pain - Dormant Projects, 2021 (Contd..2)
  • Cancer Pain - Dormant Projects, 2021 (Contd..3)
  • Cancer Pain - Discontinued Products, 2021

List of Figures

List of Figures

  • Number of Products under Development for Cancer Pain, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products by Top 10 Targets, 2021
  • Number of Products by Stage and Top 10 Targets, 2021
  • Number of Products by Top 10 Mechanism of Actions, 2021
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2021
  • Number of Products by Top 10 Routes of Administration, 2021
  • Number of Products by Stage and Top 10 Routes of Administration, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Molecule Types, 2021

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cancer Pain - Drugs In Development, 2021, provides an overview of the Cancer Pain (Central Nervous System) pipeline landscape.Cancer pain can be defined as a complex sensation that reflects both damage to the body and the body's response to the damage. Pain may arise due to tumor compressing or infiltrating tissue, from treatments and diagnostic procedures, or from skin, nerve and other changes caused by either the body's immune response or hormones released by the tumor. Cancer pain can be treated by analgesic drug therapy, non-opioid analgesics, opioid analgesics, adjuvant drugs, psychotherapy, anesthetic and neurosurgical pain management.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cancer Pain - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Cancer Pain (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Cancer Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Cancer Pain and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 7, 8, 2, 20, 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Cancer Pain (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Cancer Pain (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Cancer Pain (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Cancer Pain (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Cancer Pain (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Cancer Pain (Central Nervous System)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Cancer Pain (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Cancer Pain (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

  • Introduction
  • Cancer Pain - Overview
  • Cancer Pain - Therapeutics Development
  • Cancer Pain - Therapeutics Assessment
  • Cancer Pain - Companies Involved in Therapeutics Development
  • Cancer Pain - Drug Profiles
  • Cancer Pain - Dormant Projects
  • Cancer Pain - Discontinued Products
  • Cancer Pain - Product Development Milestones
  • Appendix
Back to Top
전화 문의
F A Q